Answers are grounded in this paper and cite their sources.
A piperacillin/tazobactam (PT) restriction was initiated at our institution on 15 July 2012 requiring clinical pharmacy or infectious diseases approval for durations exceeding 72 h. A retrospective review was undertaken to determine whether this restriction decreased PT usage and/or rates of acute renal failure (ARF) (defined as a 50% increase or 0.5 mg dl(-1) increase in serum creatinine from baseline). Patients prescribed at least 1 day of PT with a creatinine clearance of ≥ 39 ml min(-1) at the time of initiation in the 3 months prior to the restriction were compared with patients in the 5 months after restriction implementation. Overall, 115 unique patients were included in the pre-implementation group and compared with 117 unique patients in the post-implementation group. The pre-implementation group received a mean of 5.22 days of PT, compared with 4.71 days in the post-implementation group (P = 0.224). Ten per cent (12/115) of patients in the pre-implementation group developed ARF compared with 9.17% (11/120) of patients in the post-implementation group (P = 0.0309). Ninety-five patients in the pre-implementation group and 91 in the post-implementation group received combination therapy with vancomycin. ARF occurred in 11.6% (11/95) of those in the pre-implementation group and 12.1% (11/91) in the post-implementation (P>0.05). Overall, 11.8% (22/186) of patients who received therapy with PT and vancomycin developed ARF, compared with 1.7% (1/56) who received PT monotherapy (P < 0.0001). This restriction resulted in a numeric reduction in the number of PT days in the post-implementation group and a significant reduction in the rate of ARF.
No takes yet. Share an insight, caveat, or question.
Lorenz et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: